MEDCL — Medincell SA Income Statement
0.000.00%
Last trade - 00:00- €1.12bn
- €1.11bn
- €25.42m
Annual income statement for Medincell SA, fiscal year end - March 31st, EUR millions except per share, conversion factor applied.
R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.19 | 4.09 | 9.89 | 9.03 | 25.4 |
| Cost of Revenue | |||||
| Gross Profit | 6.74 | 2.59 | 6.46 | 6.77 | 24.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 23.8 | 27.9 | 33.9 | 30 | 36.3 |
| Operating Profit | -15.6 | -23.8 | -24 | -21 | -10.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19 | -24.8 | -32 | -24.9 | -18.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19 | -24.8 | -32 | -25 | -18.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -19 | -24.8 | -32 | -25 | -18.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19 | -24.8 | -32 | -25 | -18.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.861 | -0.998 | -1.27 | -0.878 | -0.62 |
| Dividends per Share |